Clinical Trial Update: A Study of Amivantamab in Participants With Previously Treated Advanced or Metastatic Gastric or Esophageal Cancer [Phase 2]

View source ↗

Summary

Phase 2 study of amivantamab in previously treated advanced or metastatic gastric or esophageal cancer was terminated; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Cancer
• Gastric Cancer

Drugs mentioned

• Amivantamab (amivantamab)

Snippet

Sponsor: Janssen Pharmaceutical K.K. | Conditions: Stomach Neoplasms, Esophageal Neoplasms | Phase 2 | Status: TERMINATED | Results posted: 2024-09-19